PureTech Health plc (LON:PRTC – Get Free Report)’s share price shot up 14.6% during trading on Friday . The company traded as high as GBX 118 ($1.54) and last traded at GBX 118 ($1.54). 1,623,564 shares changed hands during mid-day trading, an increase of 54% from the average session volume of 1,056,594 shares. The stock had previously closed at GBX 103 ($1.35).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 455 ($5.96) price target on shares of PureTech Health in a research note on Monday, December 16th.
View Our Latest Research Report on PRTC
PureTech Health Stock Performance
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Recommended Stories
- Five stocks we like better than PureTech Health
- How to Buy Cheap Stocks Step by Step
- JPMorgan is a Buy, if You Can Handle The Volatility
- Investing in Construction Stocks
- United States Steel’s Crash: An Unmissable Buying Opportunity
- Why is the Ex-Dividend Date Significant to Investors?
- Rocket Lab Stock: Weathering the Storm, Time for a Comeback?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.